Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
Tarantelli C, Cannas E, Ekeh H, Moscatello C, Gaudio E, Cascione L, Napoli S, Rech C, Testa A, Maniaci C, Rinaldi A, Zucca E, Stathis A, Ciulli A, Bertoni F. Tarantelli C, et al. Among authors: napoli s. Explor Target Antitumor Ther. 2021;2(6):586-601. doi: 10.37349/etat.2021.00065. Epub 2021 Dec 31. Explor Target Antitumor Ther. 2021. PMID: 36046113 Free PMC article.
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Johnson Z, Tarantelli C, Civanelli E, Cascione L, Spriano F, Fraser A, Shah P, Nomanbhoy T, Napoli S, Rinaldi A, Niewola-Staszkowska K, Lahn M, Perrin D, Wenes M, Migliorini D, Bertoni F, van der Veen L, Di Conza G. Johnson Z, et al. Among authors: napoli s. Cancer Res Commun. 2023 Apr 14;3(4):576-591. doi: 10.1158/2767-9764.CRC-22-0477. eCollection 2023 Apr. Cancer Res Commun. 2023. PMID: 37066023 Free PMC article.
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, Castro de Moura M, Jovic S, Bordone Pittau R, Stathis A, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F. Arribas AJ, et al. Among authors: napoli s. Mol Cancer Ther. 2024 Mar 4;23(3):368-380. doi: 10.1158/1535-7163.MCT-23-0068. Mol Cancer Ther. 2024. PMID: 38052765
Single or Blended Application of Non-Microbial Plant-Based Biostimulants and Trichoderma atroviride as a New Strategy to Enhance Greenhouse Cherry Tomato Performance.
Vultaggio L, Ciriello M, Campana E, Bellitto P, Consentino BB, Rouphael Y, Colla G, Mancuso F, La Bella S, Napoli S, Sabatino L. Vultaggio L, et al. Among authors: napoli s. Plants (Basel). 2024 Oct 31;13(21):3048. doi: 10.3390/plants13213048. Plants (Basel). 2024. PMID: 39519966 Free PMC article.
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.
Arribas AJ, Napoli S, Gaudio E, Herbaux C, Cannas E, Tarantelli C, Bordone-Pittau R, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F. Arribas AJ, et al. Among authors: napoli s. Blood Adv. 2024 Dec 24;8(24):6268-6281. doi: 10.1182/bloodadvances.2023012291. Blood Adv. 2024. PMID: 39374583 Free PMC article.
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Rentz DM, Aisen PS, Atri A, Hitchcock J, Irizarry M, Landen J, Matthews BR, Miller DS, Mahinrad S, Napoli S, Okhravi HR, Petersen RC, Siemers ER, Weber CJ, Weisman DC, Carrillo MC. Rentz DM, et al. Among authors: napoli s. Alzheimers Dement. 2024 Nov;20(11):8162-8171. doi: 10.1002/alz.14199. Epub 2024 Sep 22. Alzheimers Dement. 2024. PMID: 39306695 Free PMC article.
Long-term follow-up study on obstructive hypertrophic cardiomyopathy patients treated with disopyramide: evidences of a notable trend in symptom control within a real-world clinical setting.
Todde G, Dei LL, Polizzi R, Gabrielli D, Canciello G, Romano S, Borrelli F, Halasz G, Ordine L, Di Napoli S, Pacella D, Lombardi R, Esposito G, Re F, Losi MA. Todde G, et al. Among authors: di napoli s. Front Cardiovasc Med. 2024 Aug 14;11:1416600. doi: 10.3389/fcvm.2024.1416600. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39175632 Free PMC article.
Artificial intelligence-driven electrocardiography: Innovations in hypertrophic cardiomyopathy management.
Ordine L, Canciello G, Borrelli F, Lombardi R, Di Napoli S, Polizzi R, Falcone C, Napolitano B, Moscano L, Spinelli A, Masciari E, Esposito G, Losi MA. Ordine L, et al. Among authors: di napoli s. Trends Cardiovasc Med. 2024 Aug 13:S1050-1738(24)00075-6. doi: 10.1016/j.tcm.2024.08.002. Online ahead of print. Trends Cardiovasc Med. 2024. PMID: 39147002 Free article. Review.
130 results